Abstract：【Objective】 To investigate the application of gene testing-guided individualized medication in patients with primary hypertension. 【Methods】 A total of 164 patients with primary hypertension admitted to our hospital from June 2023 to June 2025 were enrolled and randomly divided into a control group and an observation group, with 82 patients in each group. Patients in the control group received conventional antihypertensive therapy, while those in the observation group received gene testing-guided individualized medication. Clinical efficacy, blood pressure control [systolic blood pressure (SBP), diastolic blood pressure (DBP), and blood pressure control rate], treatment adherence [Hypertension Treatment Adherence Scale], and the incidence of adverse reactions were compared between the two groups. 【Results】 The total effective rate in the observation group was higher than that in the control group, with a statistically significant difference (P<0.05). After treatment, systolic blood pressure (SBP) and diastolic blood pressure (DBP) in the observation group were lower than those in the control group, and the blood pressure compliance rate was higher than that in the control group, with statistically significant differences (P<0.05). After treatment, the scores of medication compliance behavior, avoidance of inappropriate medication behavior, management of daily living activities, smoking and alcohol habit management behavior, as well as the total compliance score in both groups were higher than those before treatment. The observation group had higher scores of medication compliance behavior, avoidance of inappropriate medication behavior and total compliance score than the control group, with a statistically significant difference (P<0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group, with a statistically significant difference (P<0.05). 【Conclusion】 Gene testing-guided individualized medication can significantly improve blood pressure control, enhance treatment adherence, and reduce drug-related adverse reactions in patients with primary hypertension, demonstrating high clinical application value.
2026, Vol. 43 
